Tivozanib Non-Oncology Buy-Back Gives Quick Cash To AVEO

In a move that will generate further useful cash for AVEO, Kyowa Kirin has reacquired global rights to non-oncology uses of tivozanib.

Kidney cancer
AVEO To Focus On Tivozanib In Renal And Other Cancers • Source: Shutterstock

Japan's Kyowa Hakko Kirin Co. Ltd. (KHK) has reacquired global rights to tivozanib in non-oncology settings from licensee Aveo Pharmaceuticals Inc., which will now focus its efforts on development and commercialization of the multi-VEGF inhibitor in the oncology field.

The move will generate further cash for the US oncology specialist, in the form of a $25m upfront payment within...

More from Strategy

More from Business